

WIPO

IP SERVICES

JP 2002500201(T)

WORLD INTELLECTUAL PROPERTY ORGANIZATION

Home IP Services PATENTSCOPE® Patent Search
 This page is being phased out of production, but will remain available during the transition to our new system.
 Please try the new [PATENTSCOPE® International and National Collections search page](#) (English only).



Search result: 1 of 1

(WO/1999/034831) ENHANCED TRANSPORT USING MEMBRANE DISRUPTIVE AGENTS

Biblio. Data	Description	Claims	National Phase	Notices	Documents
--------------	-------------	--------	----------------	---------	-----------

39

Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1999/034831 ← International Application No.: PCT/US1999/000122
 Publication Date: 15.07.1999 International Filing Date: 05.01.1999
 Chapter 2 Demand Filed: 28.07.1999

IPC: A61K 41/00 (2006.01), A61K 47/48 (2006.01)

Applicants: UNIVERSITY OF WASHINGTON [US/US]; 1107 N.E. 45th Street Seattle, WA 98105-4631 (US).
 UNIVERSITY OF MASSACHUSETTS [US/US]; Suite 800 18 Tremont Street Boston, MA 02108 (US).

Inventors: HOFFMAN, Allan, S.; (US).
 STAYTON, Patrick; (US).
 PRESS, Oliver; (US).
 TIRRELL, David; (US).
 MURTHY, Niren; (US).
 LACKEY, Chantal; (US).
 CRUM, Lawrence, A.; (US).
 MOURAD, Pierre, D.; (US).
 PORTER, Tyrone, M.; (US).

Agent: ABST, Patrea, L.; Arnall, Golden & Gregory, LLP 2800 One Atlantic Center 1201 West Peachtree Street Atlanta, GA 30309-3450 (US).

Priority Data: 60/070,411 05.01.1998 US

Title: ENHANCED TRANSPORT USING MEMBRANE DISRUPTIVE AGENTS

Abstract: Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes, coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered. Agents to be delivered can be therapeutic and/or diagnostic agents. Treatments which enhance delivery such as ultrasound, iontophoresis, and/or electrophoresis can also be used with the disrupting agents.

Designated States: AU, CA, JP.
 European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Publication Language: English (EN)
 Filing Language: English (EN)

ENHANCED TRANSPORT USING MEMBRANE DISRUPTIVE AGENTS

Publication number: JP2002500201 (T)

Publication date: 2002-01-08

Inventor(s):

Applicant(s):

Classification:

- International:

A61K31/7105; A61K31/711; A61K41/00; A61K47/32;
A61K47/42; A61K47/48; A61K9/00; A61K31/7105;
A61K31/711; A61K41/00; A61K47/32; A61K47/42;
A61K47/48; A61K9/00; (IPC-1-7): A61K31/7105; A61K31/711;
A61K47/32; A61K47/42; A61K47/48; A61K9/00

- European:

A61K41/00M; A61K41/00T; A61K47/48T2

Application number: JP20000527278T 19990105

Priority number(s): US19980070411P 19980105; WO1999US00122 19980105

Also published as:

WO9934831 (A1)
EP1044021 (A1)
EP1044021 (B1)
EP2138191 (A1)
CA2317549 (A1)

more >>

Abstract not available for JP 2002500201 (T)

Abstract of corresponding document: WO 9934831 (A1)

Compositions and methods for transport or release of therapeutic and diagnostic agents or metabolites or other analytes from cells, compartments within cells, or through cell layers or barriers are described. The compositions include a membrane barrier transport enhancing agent and are usually administered in combination with an enhancer and/or exposure to stimuli to effect disruption or altered permeability, transport or release. In a preferred embodiment, the compositions include compounds which disrupt endosomal membranes in response to the low pH in the endosomes but which are relatively inactive toward cell membranes, coupled directly or indirectly to a therapeutic or diagnostic agent. Other disruptive agents can also be used, responsive to stimuli and/or enhancers other than pH, such as light, electrical stimuli, electromagnetic stimuli, ultrasound, temperature, or combinations thereof. The compounds can be coupled by ionic, covalent or H bonds to an agent to be delivered or to a ligand which forms a complex with the agent to be delivered. Agents to be delivered can be therapeutic and/or diagnostic agents. Treatments which enhance delivery such as ultrasound, iontophoresis, and/or electroporesis can also be used with the disrupting agents.

Data supplied from the **espacenet** database — Worldwide